Isogenica and Phylogica collaborate

Isogenica of Cambridge, UK has agreed with Australian biopharmaceutical company Phylogica to use its CIS display technology to optimise the performance of three of Phylogica's lead compounds targeting CD40 ligand (CD40L).

Isogenica of Cambridge, UK has agreed with Australian biopharmaceutical company Phylogica to use its CIS display technology to optimise the performance of three of Phylogica's lead compounds targeting CD40 ligand (CD40L).

CD40L is a key protein involved in many inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.

Isogenica specialises in the discovery of therapeutic and diagnostic peptides and proteins using its CIS display technology.

Perth-based Phylogica focuses on the discovery, development and commercialisation of Phylomer peptides, especially for inflammatory diseases.

"We believe that the use of CIS display will accelerate the rapid entry of Phylogica drug candidates into preclinical development programmes and increase their commercial value," said Professor Paul Watt, Phylogica's vp, Corporate Development.

Phylogica joins more than a dozen pharmaceutical and biotech companies already partnering Isogenica, including Amgen, AstraZeneca, Centocor, GE Healthcare, Invitrogen, Johnson & Johnson, Pfizer, Smiths Detection Systems, UCB and Wyeth.




Companies